EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

Tobias Koch iD, Shqipdona Lahu, J J Coughlan, Salvatore Cassese, Felix Voll, Gjin Ndrepepa, Maurizio Menichelli, Christian Valina, Rayyan Hemetsberger, Bernhard Witzenbichler, Isabell Bernlochner, Michael Joner und 10 weitere

Thrombosis and Haemostasis · 01.04.2023 · 123 (04) · 464-477

DOI: 10.1055/a-1988-5047 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.04.2023. Verfasst von Tobias Koch und 21 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The relative efficacy and safety of ticagrelor and prasugrel based dual antiplatelet therapy strategies according to the platelet count (PC) in patients with acute coronary syndromes (ACS) have not been defined.

Methods

This is a posthoc analysis of the ISAR-REACT 5 trial, in which patients presenting with ACS were randomized to treatment with ticagrelor versus prasugrel. Patients were divided into quartiles according to PC. The primary endpoint was incidence of death, myocardial infarction, or stroke, and the safety endpoint was incidence of BARC (Bleeding Academic Research Consortium) type 3 to 5 bleeding at 12 months.

Results

A total of 3,943 patients with known PC (997 patients in quartile 1 (Q1), 1,003 in quartile 2 (Q2) [205 ± 10.3 × 109/L], 961 patients in quartile 3 (Q3) [241 ± 11.7 × 109/L], and 982 patients in quartile 4 (Q4) [317 ± 68.6 × 109/L]). There was no significant interaction between treatment arm (ticagrelor vs. prasugrel) and PC group with respect to primary endpoint (Q1: 8.8 vs. 6.3%, hazard ratio [HR] =1.41, 95% confidence interval [CI]: 0.89–2.23; p = 0.148; Q2: 9.9 vs. 5.8%, HR = 1.68, 95% CI: 1.06–2.66; p = 0.027; Q3: 7.8 vs. 5.5%, HR = 1.43, 95% CI: 0.87–2.37; p = 0.159; Q4: 10.1 vs. 10.1%, HR = 1.05, 95% CI: 0.71–1.57; p = 0.799; p for interaction [p int] = 0.482) and with respect to bleeding endpoint (Q1: 5.8 vs. 4.2%, HR = 1.41, 95% CI: 0.76–2.63; p = 0.279; Q2: 6.4 vs. 3.7%, HR = 1.62, 95% CI: 0.85–2.06; p = 0.140; Q3: 4.4 vs. 3.0%, HR = 1.53, 95% CI: 0.73–3.18; p = 0.258; Q4: 5.6 vs. 8.5%, HR = 0.67, 95% CI: 0.40–1.14; p = 0.138, p int = 0.102).

Conclusions

In this analysis, incidences of ischemic and bleeding events at 12 months are comparable across quartiles of platelet count.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionHumansPrasugrel HydrochlorideTicagrelorPlatelet Aggregation InhibitorsPlatelet CountTreatment OutcomeHemorrhage

Substanzen

Prasugrel HydrochlorideTicagrelorPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
  • Ospedale Fabrizio Spaziani, Cardiology, Frosinone, Italy.
  • Department of Cardiology and Angiology II, University Heart Center Freiburg - Bad Krozingen, Standort Bad Krozingen, Germany.
  • Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
  • Helios Amper-Klinikum Dachau, Cardiology and Pneumology, Dachau, Germany.
  • Medizinische Klinik und Poliklinik Innere Medizin I (Kardiologie, Angiologie, Pneumologie), Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

ORCID-Profile: Tobias Koch, Erion Xhepa, Dominick J Angiolillo, Adnan Kastrati

Zitieren

APA

Koch, T., Lahu, S., Coughlan, J. J., Cassese, S., Voll, F., Ndrepepa, G., Menichelli, M., Valina, C., Hemetsberger, R., Witzenbichler, B., Bernlochner, I., Joner, M., Xhepa, E., Mayer, K., Kessler, T., Laugwitz, K. L., Richardt, G., Schunkert, H., Angiolillo, D. J., …, & Kufner, S. (2023). Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. Thrombosis and Haemostasis, 123(04), 464-477. https://doi.org/10.1055/a-1988-5047

Vancouver

Koch T, Lahu S, Coughlan JJ, Cassese S, Voll F, Ndrepepa G, et al. Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. Thrombosis and Haemostasis. 2023;123(04):464-477. doi:10.1055/a-1988-5047

BibTeX
@article{Koch2023,
  author = {Koch, Tobias and Lahu, Shqipdona and Coughlan, J J and Cassese, Salvatore and Voll, Felix and Ndrepepa, Gjin and Menichelli, Maurizio and Valina, Christian and Hemetsberger, Rayyan and Witzenbichler, Bernhard and Bernlochner, Isabell and Joner, Michael and Xhepa, Erion and Mayer, Katharina and Kessler, Thorsten and Laugwitz, Karl-Ludwig and Richardt, Gert and Schunkert, Heribert and Angiolillo, Dominick J and Sibbing, Dirk and Kastrati, Adnan and Kufner, Sebastian},
  title = {Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes},
  journal = {Thrombosis and Haemostasis},
  year = {2023},
  volume = {123},
  number = {04},
  pages = {464--477},
  doi = {10.1055/a-1988-5047}
}
Kostenlos starten →